Publications by authors named "Silvia Urbina"
Article Synopsis
- YG1699 is a new drug that inhibits the SGLT1 and SGLT2 transporters and was tested alongside dapagliflozin in a study involving adults with type 1 diabetes on insulin pump therapy.
- The trial involved a double-blind, 3-way crossover design where participants received different doses of YG1699 and dapagliflozin, with the main focus on how these drugs affected plasma glucose levels after meals.
- Results showed that YG1699 significantly lowered post-meal glucose levels and reduced insulin requirements compared to dapagliflozin, while the overall safety of both treatments appeared similar.
Introduction: Excess body fat is linked to higher risks for metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CV), among other health conditions. However, it is not only the level but also the distribution of body fat that contributes to increased disease risks. For example, an increased level of abdominal fat, or visceral adipose tissue (VAT), is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
View Article and Find Full Text PDF